Mode
Text Size
Log in / Sign up
N/A N=191 Randomized Treatment

Responsive e-Health Intervention for Perinatal Depression in Healthcare Settings

Perinatal Depression

Enrolled (actual)
191
Serious AEs
0.0%
Results posted
Oct 2023
Primary outcome: Primary: Change in Primary Health Questionnaire (PHQ-9) — 10.68; 10.24; 5.78; 7.48 score on a scale — p=.003

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Treatment As Usual + MMB 2.0 (Behavioral); Treatment As Usual Only (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
Oregon Research Behavioral Intervention Strategies, Inc.
Primary completion
May 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Primary Health Questionnaire (PHQ-9)
10.68; 10.24; 5.78; 7.48 .003 sig
SECONDARY
Change in General Anxiety Disorder (GAD)
5.23; 5.96; 2.81; 4.12 .283
SECONDARY
Change in Stress
9.61; 10.36; 5.79; 8.10 .019 sig
SECONDARY
Change in Behavioral Activation for Depression Scale (BADS)
25.15; 24.46; 31.15; 29.37 .440
SECONDARY
Change in Automatic Thoughts Questionnaire - Short Form (ATQ)
1.23; 1.24; 0.72; 0.90 .055
SECONDARY
Change in Self-Efficacy
2.86; 2.77; 3.40; 3.05 .041 sig

Summary

Perinatal depression is experienced by at least 14-20% of pregnant and postpartum women, and is recognized as the most common complication of childbirth. In this project, the investigators plan to complete the process of making MomMoodBooster (MMB), a web-based cognitive-behavioral depression intervention, into a commercial ready product, MMB 2.0, that fits the workflow and staffing of healthcare organizations and is designed for both prenatal and postpartum women who are depressed. The investigators will also conduct a 2-arm randomized controlled trial to evaluate the efficacy of treatment as usual plus MMB 2.0 compared to treatment as usual in a large healthcare setting.

Eligibility Criteria

Inclusion Criteria

  • pregnant or postpartum
  • have elevated Edinburgh Postnatal Depression Scale (EPDS) of ≥ 12
  • access to broadband internet and a computer at home (desktop, laptop, tablet) or a smartphone (iOS or Android)
  • English language proficiency sufficient to enable completion of the informed consent and to engage in all study activities that are delivered in English

Exclusion Criteria

  • Women assessed with active suicidal ideation will be excluded and provided with immediate psychiatric care consistent with NorthShore's established safety protocol
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03995316). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search